Precision Biosciences (DTIL) EBIT Margin (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of EBIT Margin data on file, last reported at 83.73% in Q1 2026.

• On a quarterly basis, EBIT Margin rose 7616454.0% year-over-year to 83.73% in Q1 2026; TTM through Mar 2026 was 86.77%, a 57.0% decrease from a year earlier, with the FY2025 full-year figure at 152.19%, down 11411.0% from the prior year.
• EBIT Margin for Q1 2026 stood at 83.73%, down from 36.57% in the prior quarter.
• Over the last five years, EBIT Margin for DTIL reached as high as 48.39% in Q2 2024 and fell as low as 158976.92% in Q3 2025.
• Historically, EBIT Margin has averaged 21574.1% across 5 years, with a median of 199.32% in 2022.
• Across the five-year window, EBIT Margin tumbled 15528335 bps in 2025 and jumped 7616454 bps in 2026, its largest moves.
• Year by year, EBIT Margin stood at 114.26% in 2022, then tumbled by 85 bps to 211.57% in 2023, then plunged by 1741 bps to 3894.36% in 2024, then soared by 101 bps to 36.57% in 2025, then plunged by 329 bps to 83.73% in 2026.
• Per Business Quant data, the three most recent EBIT Margin figures were 83.73% in Q1 2026, 36.57% in Q4 2025, and 158976.92% in Q3 2025.